4.0878
4.52%
-0.1122
시간 외 거래:
4.0878
Marker Therapeutics Inc 주식(MRKR)의 최신 뉴스
Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates - GlobeNewswire
GlobeNewswire
Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
GlobeNewswire Inc.
Form 10-Q Marker Therapeutics, For: Mar 31 - StreetInsider.com
StreetInsider.com
Unlocking ferroptosis in prostate cancer — the road to novel therapies and imaging markers - Nature.com
Nature.com
Eliem Therapeutics agrees to acquire Tenet - Pharmaceutical Technology
Pharmaceutical Technology
Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies
GlobeNewswire Inc.
Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker ... - GlobeNewswire
GlobeNewswire
MRKR Stock Quote Price and Forecast - CNN
CNN
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results
GlobeNewswire Inc.
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results - Yahoo Finance
Yahoo Finance
Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
GlobeNewswire Inc.
Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference - GlobeNewswire
GlobeNewswire
Madrigal stock in focus as FDA clears NASH drug (NASDAQ:MDGL) - Seeking Alpha
Seeking Alpha
Intellia Therapeutics, Inc. (NTLA) Crossed Above the 50-Day Moving Average: What That Means for Investors - Zacks Investment Research
Zacks Investment Research
Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601
GlobeNewswire Inc.
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization
GlobeNewswire Inc.
NightHawk Changes Name To Scorpius Holdings - Contract Pharma
Contract Pharma
Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”
GlobeNewswire Inc.
AML cell therapy trials to watch in 2024 targeting GvHD - Clinical Trials Arena
Clinical Trials Arena
Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates - GlobeNewswire
GlobeNewswire
Marker Therapeutics Inc's Uncertain Future: Understanding the Barriers to Outperformance - Yahoo Finance
Yahoo Finance
Acute Myeloid Leukemia Market Size and Share to Rise by 2032, Predicts DelveInsight | Key Companies - Chimerix ... - Yahoo Finance
Yahoo Finance
Hematopoietic Stem Cell Transplantation Global Market Report 2023 - Yahoo Finance
Yahoo Finance
Denali Therapeutics Announces Robust Reduction in Neurofilament Light (NfL) with DNL310 (ETV:IDS) Treatment in ... - GlobeNewswire
GlobeNewswire
Why Motorcar Parts of America Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Tuesday’s - Benzinga
Benzinga
Why Asset Entities Shares Are Trading Higher By 142%? Here Are Other Stocks Moving In Monday’s Mid-Day Se - Benzinga
Benzinga
Top Small-Cap Stocks for June 2023 - Investopedia
Investopedia
A Promising Drug Delivery Method Could Replace Injections with Pills - Lab Manager Magazine
Lab Manager Magazine
Nasdaq Down 100 Points; Advance Auto Parts Earnings Miss Views - Markets Insider
Markets Insider
FDA reviewers raise doubts over data on Sarepta's gene therapy - Reuters
Reuters
Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer - GlobeNewswire
GlobeNewswire
Marker to offload cell manufacturing assets to CellReady - Pharmaceutical Technology
Pharmaceutical Technology
7 Low Float Penny Stocks To Watch After SNTG Stock Explodes - Penny Stocks
Penny Stocks
Allogeneic cell therapy approval to pave the way for future therapies in this class - Clinical Trials Arena
Clinical Trials Arena
Zentalis to present positive clinical data in ovarian cancer combining azenosertib and chemotherapy, including clinical ... - GlobeNewswire
GlobeNewswire
Legend Biotech appoints former Eli Lilly oncology expert as chief medical officer - ROI-NJ.com
ROI-NJ.com
An Invisible Skin Marker for External Beam Radiation Therapy: Utilization of Ultraviolet Fluorescent Marker Pens - Cureus
Cureus
Cotações de Ações Americanas: Bolsas ao vivo e últimas notícias - Money Times
Money Times
Replication competent retrovirus testing (RCR) in the National Gene Vector Biorepository: No evidence of RCR in 1595 ... - ScienceDirect.com
ScienceDirect.com
SSTR2 as an anatomical imaging marker and a safety switch to monitor and manage CAR T cell toxicity | Scientific ... - Nature.com
Nature.com
Immune checkpoint therapy: Forging ahead - Science
Science
The Top 25 Healthcare Technology Leaders of Los Angeles for 2022 - The Healthcare Technology Report.
The Healthcare Technology Report.
Mohamad Makhzoumi Net Worth (2024) - GuruFocus.com
GuruFocus.com
ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly ... - Nature.com
Nature.com
Terumo, Eliaz partner to improve outcomes for acute kidney injury - BioWorld Online
BioWorld Online
Data Breach Alert: The Marker Group, Inc. | Console and Associates, P.C. - JDSupra - JD Supra
JD Supra
Donor-Derived Adoptive T-Cell Therapy Targeting Multiple Tumor Associated Antigens to Prevent Post-Transplant ... - ScienceDirect.com
ScienceDirect.com
Pancreatic Cancer Pipeline Review | A Drug Pipeline Analysis Report 2021 | DelveInsight - GlobeNewswire
GlobeNewswire
27 Stocks Moving in Friday's Pre-Market Session - Atlantic American (NASDAQ:AAME), Aemetis (NASDAQ:AMTX) - Benzinga
Benzinga
Therapy for Alzheimer's disease: Missing targets and functional markers? - ScienceDirect.com
ScienceDirect.com
자본화:
|
볼륨(24시간):